A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP

Open source

DOI: 10.1186/s13046-022-02383-5
Published: 2022 Jun 2
Container: Journal of experimental & clinical cancer research : CR
Publisher: figshare
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13046-022-02383-5,
  title = {A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.},
  author = {Chan SL and Schuler M and Kang YK and Yen CJ and Edeline J and Choo SP and Lin CC and Okusaka T and Weiss KH and Macarulla T and Cattan S and Blanc JF and Lee KH and Maur M and Pant S and Kudo M and Assenat E and Zhu AX and Yau T and Lim HY and Bruix J and Geier A and Guillén-Ponce C and Fasolo A and Finn RS and Fan J and Vogel A and Qin S and Riester M and Katsanou V and Chaudhari M and Kakizume T and Gu Y and Porta DG and Myers A and Delord JP},
  year = {2022},
  journal = {Journal of experimental \& clinical cancer research : CR},
  doi = {10.1186/s13046-022-02383-5},
  url = {https://doi.org/10.1186/s13046-022-02383-5}
}

RIS

TY  - JOUR
TI  - A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
AU  - Chan SL
AU  - Schuler M
AU  - Kang YK
AU  - Yen CJ
AU  - Edeline J
AU  - Choo SP
AU  - Lin CC
AU  - Okusaka T
AU  - Weiss KH
AU  - Macarulla T
AU  - Cattan S
AU  - Blanc JF
AU  - Lee KH
AU  - Maur M
AU  - Pant S
AU  - Kudo M
AU  - Assenat E
AU  - Zhu AX
AU  - Yau T
AU  - Lim HY
AU  - Bruix J
AU  - Geier A
AU  - Guillén-Ponce C
AU  - Fasolo A
AU  - Finn RS
AU  - Fan J
AU  - Vogel A
AU  - Qin S
AU  - Riester M
AU  - Katsanou V
AU  - Chaudhari M
AU  - Kakizume T
AU  - Gu Y
AU  - Porta DG
AU  - Myers A
AU  - Delord JP
PY  - 2022
JO  - Journal of experimental & clinical cancer research : CR
DO  - 10.1186/s13046-022-02383-5
UR  - https://doi.org/10.1186/s13046-022-02383-5
ER  -

APA

SL, C., M, S., YK, K., CJ, Y., J, E., SP, C., CC, L., T, O., KH, W., T, M., S, C., JF, B., KH, L., M, M., S, P., M, K., E, A., AX, Z., T, Y., HY, L., J, B., A, G., C, G., A, F., RS, F., J, F., A, V., S, Q., M, R., V, K., M, C., T, K., Y, G., DG, P., A, M., & JP, D. (2022). A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.. Journal of experimental & clinical cancer research : CR. https://doi.org/10.1186/s13046-022-02383-5

Source records

pubmed · retrieved 2026-09-26T01:29:02.669Z
europe-pmc · retrieved 2026-09-26T01:29:02.674Z
datacite · retrieved 2026-09-26T01:29:02.657Z
datacite · retrieved 2026-09-26T01:29:02.657Z
hal · retrieved 2026-09-26T01:29:02.719Z